

Remarks


Applicant submits the foregoing amendment to the Specification prior to examination to correct two typographical errors. In reviewing the filed application, Applicant noted that the second column of the Table on page 35 had inadvertently omitted the last digit of the numbers. It should be noted that, as filed, the percent inhibition values set out under the 10mM molarity do not make sense in the context of the Table. Applicant also noted that the triangle symbol at line 7, page 30 of the specification was not printed by the printer.

No new matter has been added.

Based on the foregoing, this application is believed to be in condition for allowance. A Notice to that effect is respectfully solicited. If the Examiner has any questions with respect to this matter, the Examiner is respectfully requested to contact the undersigned in an effort to expedite prosecution.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 
Robin L. Teskin
Registration No. 35, 030

1100 New York Avenue, N.W.
Ninth Floor, East Tower
Washington, D.C. 20005
(202) 861-3000
(202) 822-0944 Facsimile

Date: April 19, 2001

APPENDIX

In the Specification:

Page 29, please delete the paragraph beginning at line 7 (which bridges over to page 30) and replace it with the following paragraph:

□, human CRP in untreated rats; ▲, human CRP in rats decompemented by i.p. injection of 250 U/kg of cobra venom factor 24 h beforehand; ●, human SAP in untreated rats.

Page 35, please delete Table 1 in its entirety and replace it with the following Table:

Table 1

Percent Inhibition by Various Compounds of Binding of
Radiolabelled CRP to
Immobilized Enzyme Modified Low Density Lipoprotein

Compound	Molarity				
	10 mM	1 mM	100 µM	10 µM	1 µM
None	<u>0</u>	0	0	0	0
Phosphoethanolamine	<u>92</u>	90	39	0	0
Phosphocholine	<u>95</u>	94	93	46	0
Hexadecyl phosphocholine	<u>94</u>	73	76	0	0
Phosphoserine	<u>38</u>	0	0	0	0